Immunovant Inc’s recently made public that its Chief Technology Officer Stout Jay S unloaded Company’s shares for reported $0.21 million on Apr 24 ’24. In the deal valued at $28.90 per share,7,239 shares were sold. As a result of this transaction, Stout Jay S now holds 147,739 shares worth roughly $4.37 million.
Then, Levine Mark S. sold 3,963 shares, generating $114,531 in total proceeds. Upon selling the shares at $28.90, the Chief Legal Officer now owns 343,156 shares.
Before that, Geffner Michael sold 3,261 shares. Immunovant Inc shares valued at $94,243 were divested by the Chief Medical Officer at a price of $28.90 per share. As a result of the transaction, Geffner Michael now holds 141,616 shares, worth roughly $4.19 million.
Oppenheimer initiated its Immunovant Inc [IMVT] rating to an Outperform in a research note published on March 28, 2024; the price target was $50. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. JP Morgan began covering IMVT with “an Overweight” recommendation on February 20, 2024. Wolfe Research started covering the stock on February 15, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Tuesday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -0.30% to $29.58. Over the last five days, the stock has gained 7.80%. Immunovant Inc shares have fallen nearly -29.79% since the year began. Nevertheless, the stocks have risen 54.06% over the past one year. While a 52-week high of $45.58 was reached on 01/09/24, a 52-week low of $17.53 was recorded on 04/30/24. SMA at 50 days reached $31.01, while 200 days put it at $32.36. A total of 0.59 million shares were traded, compared to the trading of 0.68 million shares in the previous session.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 29.07, which if violated will result in even more drops to 28.56. On the upside, there is a resistance level at 29.89. A further resistance level may holdings at 30.20. The Relative Strength Index (RSI) on the 14-day chart is 50.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.95, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 20.73%. Stochastics %K at 69.76% indicates the stock is a holding.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
